File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

TitleAnalysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens
Authors
Issue Date2021
Citation
Breast Cancer Res Treat, 2021 How to Cite?
Persistent Identifierhttp://hdl.handle.net/10722/304989

 

DC FieldValueLanguage
dc.contributor.authorDai, MS-
dc.contributor.authorFeng, YH-
dc.contributor.authorChen, SW-
dc.contributor.authorMasuda, N-
dc.contributor.authorYau, TCC-
dc.contributor.authorChen, ST-
dc.contributor.authorLu, YS-
dc.contributor.authorYap, YS-
dc.contributor.authorAng, PCS-
dc.contributor.authorChu, SC-
dc.contributor.authorKwong, A-
dc.contributor.authorLee, KS-
dc.contributor.authorOw, S-
dc.contributor.authorKim, SB-
dc.contributor.authorLin, J-
dc.contributor.authorChung, HC-
dc.contributor.authorNgan, R-
dc.contributor.authorKok, VC-
dc.contributor.authorRau, KM-
dc.contributor.authorSangai, T-
dc.contributor.authorNg, TY-
dc.contributor.authorTseng, LM-
dc.contributor.authorBryce, R-
dc.contributor.authorBebchuk, J-
dc.contributor.authorChen, MC-
dc.contributor.authorHou, MF-
dc.date.accessioned2021-10-05T02:38:08Z-
dc.date.available2021-10-05T02:38:08Z-
dc.date.issued2021-
dc.identifier.citationBreast Cancer Res Treat, 2021-
dc.identifier.urihttp://hdl.handle.net/10722/304989-
dc.languageeng-
dc.relation.ispartofBreast Cancer Res Treat-
dc.titleAnalysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens-
dc.typeArticle-
dc.identifier.emailYau, TCC: tyaucc@hku.hk-
dc.identifier.emailKwong, A: avakwong@hku.hk-
dc.identifier.authorityYau, TCC=rp01466-
dc.identifier.authorityKwong, A=rp01734-
dc.identifier.doi10.1007/s10549-021-06313-5-
dc.identifier.hkuros326273-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats